Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers

R. T. Eagan, S. Frytak, W. C. Nichols, J. N. Ingle, E. T. Creagan, L. K. Kvols

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Forty-seven patients with squamous cell or small cell lung cancer (28 [16%] of whom had cardiac disease too severe to permit the use of doxorubicin) were treated with cyclophosphamide and VP-16-213 with or without cisplatin. Four of 11 patients with squamous cell (36%) and 19 of 24 patients with small cell (79%) cancers had tumor regressions (eight complete regressions) on the three-drug regimen. Median survival times for the 31 patinets with small cell lung cancer were 9 months for those with extensive disease and 12.2 months for those with limited disease. The data suggest that the roles of VP-16-213 and cisplatin need further evaluation in these cell types and that doxorubicin may not be mandatory for successful treatment of squamous cell and small cell lung cancers.

Original languageEnglish (US)
Pages (from-to)453-458
Number of pages6
JournalCancer Treatment Reports
Volume65
Issue number5-6
StatePublished - 1981
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cyclophosphamide
Cisplatin
Epithelial Cells
Doxorubicin
Heart Diseases
Neoplasms
Survival
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eagan, R. T., Frytak, S., Nichols, W. C., Ingle, J. N., Creagan, E. T., & Kvols, L. K. (1981). Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. Cancer Treatment Reports, 65(5-6), 453-458.

Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. / Eagan, R. T.; Frytak, S.; Nichols, W. C.; Ingle, J. N.; Creagan, E. T.; Kvols, L. K.

In: Cancer Treatment Reports, Vol. 65, No. 5-6, 1981, p. 453-458.

Research output: Contribution to journalArticle

Eagan, RT, Frytak, S, Nichols, WC, Ingle, JN, Creagan, ET & Kvols, LK 1981, 'Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers', Cancer Treatment Reports, vol. 65, no. 5-6, pp. 453-458.
Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. Cancer Treatment Reports. 1981;65(5-6):453-458.
Eagan, R. T. ; Frytak, S. ; Nichols, W. C. ; Ingle, J. N. ; Creagan, E. T. ; Kvols, L. K. / Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 5-6. pp. 453-458.
@article{1b7d2a358a6f4e3e8bc9ce55bb0e7054,
title = "Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers",
abstract = "Forty-seven patients with squamous cell or small cell lung cancer (28 [16{\%}] of whom had cardiac disease too severe to permit the use of doxorubicin) were treated with cyclophosphamide and VP-16-213 with or without cisplatin. Four of 11 patients with squamous cell (36{\%}) and 19 of 24 patients with small cell (79{\%}) cancers had tumor regressions (eight complete regressions) on the three-drug regimen. Median survival times for the 31 patinets with small cell lung cancer were 9 months for those with extensive disease and 12.2 months for those with limited disease. The data suggest that the roles of VP-16-213 and cisplatin need further evaluation in these cell types and that doxorubicin may not be mandatory for successful treatment of squamous cell and small cell lung cancers.",
author = "Eagan, {R. T.} and S. Frytak and Nichols, {W. C.} and Ingle, {J. N.} and Creagan, {E. T.} and Kvols, {L. K.}",
year = "1981",
language = "English (US)",
volume = "65",
pages = "453--458",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5-6",

}

TY - JOUR

T1 - Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers

AU - Eagan, R. T.

AU - Frytak, S.

AU - Nichols, W. C.

AU - Ingle, J. N.

AU - Creagan, E. T.

AU - Kvols, L. K.

PY - 1981

Y1 - 1981

N2 - Forty-seven patients with squamous cell or small cell lung cancer (28 [16%] of whom had cardiac disease too severe to permit the use of doxorubicin) were treated with cyclophosphamide and VP-16-213 with or without cisplatin. Four of 11 patients with squamous cell (36%) and 19 of 24 patients with small cell (79%) cancers had tumor regressions (eight complete regressions) on the three-drug regimen. Median survival times for the 31 patinets with small cell lung cancer were 9 months for those with extensive disease and 12.2 months for those with limited disease. The data suggest that the roles of VP-16-213 and cisplatin need further evaluation in these cell types and that doxorubicin may not be mandatory for successful treatment of squamous cell and small cell lung cancers.

AB - Forty-seven patients with squamous cell or small cell lung cancer (28 [16%] of whom had cardiac disease too severe to permit the use of doxorubicin) were treated with cyclophosphamide and VP-16-213 with or without cisplatin. Four of 11 patients with squamous cell (36%) and 19 of 24 patients with small cell (79%) cancers had tumor regressions (eight complete regressions) on the three-drug regimen. Median survival times for the 31 patinets with small cell lung cancer were 9 months for those with extensive disease and 12.2 months for those with limited disease. The data suggest that the roles of VP-16-213 and cisplatin need further evaluation in these cell types and that doxorubicin may not be mandatory for successful treatment of squamous cell and small cell lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=0019417059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019417059&partnerID=8YFLogxK

M3 - Article

C2 - 6263477

AN - SCOPUS:0019417059

VL - 65

SP - 453

EP - 458

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5-6

ER -